SCHEMBL5164419

SCHEMBL5164419

N#Cc1ccccc1-c1ccc(C[C@H](N)C(=O)O)cc1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.57
ALPI P09923 1/20 0.57
PKM P14618 1/20 0.57
PTGS1 P23219 1/20 0.57
XIAP P98170 1/20 0.57
MME P08473 1/20 0.56
ITGB1 P05556 1/20 0.53
ITGA4 P13612 1/20 0.53
FFAR1 O14842 1/20 0.53
AKR1B1 P15121 1/20 0.53
ESR2 Q92731 1/20 0.50
PTPN1 P18031 2/20 0.49
DPP8 Q6V1X1 1/20 0.47
TPH1 P17752 9/20 0.47
CTSC P53634 1/20 0.44
PTPN5 P54829 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5164414 1.00 SLC7A5 (0.57) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL2846869 0.87 MME (0.59) MMEITGB1ITGA4FFAR1AKR1B1
SCHEMBL8316621 0.85 ITGB1 (0.55) MMEITGB1ITGA4FFAR1AKR1B1
SCHEMBL7177998 0.84 MME (0.52) MMEITGB1ITGA4FFAR1AKR1B1
SCHEMBL180446 0.84 SLC7A5 (0.70) SLC7A5ALPIPKMPTGS1XIAP
Hydrochloric Acid SCHEMBL5262184 0.83 MME (0.51) MMEITGB1ITGA4FFAR1AKR1B1
Hydrochloric Acid SCHEMBL5262181 0.83 MME (0.51) MMEITGB1ITGA4FFAR1AKR1B1
Hydrochloric Acid SCHEMBL7569042 0.82 SLC7A5 (0.68) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL8312930 0.82 MME (0.54) MMEITGB1ITGA4FFAR1AKR1B1
SCHEMBL8445937 0.80 MME (0.53) MMEITGB1ITGA4FFAR1AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1017382-A4 BIARYLALKANOIC ACIDS AS CELL ADHESION INHIBITORS MERCK & CO INC (US) 2000-08-30 EP claimed
EP-1017382-A1 BIARYLALKANOIC ACIDS AS CELL ADHESION INHIBITORS Merck & Co., Inc. (a New Jersey corp.) (US) 2000-07-12 EP claimed
WO-1998053817-A1 BIARYLALKANOIC ACIDS AS CELL ADHESION INHIBITORS MERCK & CO., INC. (US) 1998-12-03 WO claimed
EP-1763361-A2 STEROID SPARING AGENTS AND THEIR USE Elan Pharmaceuticals, Inc. (US) 2007-03-21 EP disclosed
WO-2005097162-A2 STEROID SPARING AGENTS AND THEIR USE ELAN PHARMACEUTICALS, INC. (US) 2005-10-20 WO disclosed
US-6734311-B2 ANTIINFLAMMATORY AGENTS; ALZHEIMER'S DISEASE; CARDIOVASCULAR DISORDERS MERCK & CO., INC. 2004-05-11 US disclosed
US-6579889-B2 Alzheier's diseases; antiallergens; vision defects; antihistamines; skin disorders MERCK & CO., INC. 2003-06-17 US disclosed
US-20030092746-A1 Substituted amidine derivatives as inhibitors of cell adhesion MERCK & CO., INC. 2003-05-15 US disclosed
US-6482840-B2 TREATMENT OF AIDS-RELATED DEMENTIA, ALLERGIC CONJUNCTIVITIS, ALLERGIC RHINITIS, ALZHEIMER'S DISEASE, ASTHMA, ATHEROSCLEROSIS, AUTOLOGOUS BONE MARROW TRANSPLANTATION, INFLAMMATORY LUNG DISEASES, MENINGITIS, MULTIPLE SCLEROSIS MERCK & CO., INC. 2002-11-19 US disclosed
US-6403584-B1 CONJUNCTIVITIS, ALLERGIC RHINITIS, ALZHEIMER'S DISEASE, ASTHMA, ATHEROSCLEROSIS, AUTOLOGOUS BONE MARROW TRANSPLANTATION, ANTIINFLAMMATORY, ETC MERCK & CO., INC. 2002-06-11 US disclosed
US-6353099-B1 USED FOR PREVENTION OR TREATMENT OF DISEASES, DISORDERS, CONDITIONS OR SYMPTOMS MEDIATED BY CELL ADHESION IN MAMMAL MERCK & CO., INC. 2002-03-05 US disclosed
US-20020019419-A1 Substituted isonipecotyl derivatives as inhibitors of cell adhesion MERCK & CO., INC. 2002-02-14 US disclosed
US-20020010199-A1 Substituted cyclic amidine derivatives as inhibitors of cell adhesion MERCK SHARP & DOHME CORP. 2002-01-24 US disclosed
US-6291511-B1 Biarylalkanoic acids as cell adhesion inhibitors MERCK & CO., INC. 2001-09-18 US disclosed
EP-1017382-A4 BIARYLALKANOIC ACIDS AS CELL ADHESION INHIBITORS MERCK & CO INC (US) 2000-08-30 EP disclosed
EP-1017382-A1 BIARYLALKANOIC ACIDS AS CELL ADHESION INHIBITORS Merck & Co., Inc. (a New Jersey corp.) (US) 2000-07-12 EP disclosed
WO-1998053817-A1 BIARYLALKANOIC ACIDS AS CELL ADHESION INHIBITORS MERCK & CO., INC. (US) 1998-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092746-A1 Substituted amidine derivatives as inhibitors of cell adhesion VCAM1, CD4, ICAM1 SLC7A5 2697/4885ALPI 85/4885PKM 2955/4885
US-20020010199-A1 Substituted cyclic amidine derivatives as inhibitors of cell adhesion VCAM1, CD4, ICAM1 SLC7A5 3120/4885ALPI 92/4885PKM 2646/4885
US-20020019419-A1 Substituted isonipecotyl derivatives as inhibitors of cell adhesion VCAM1, ICAM1, CD4 SLC7A5 4686/4885ALPI 101/4885PKM 3365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.